



2022 EFPIA Patient Organisation Methodological Note – Eli Lilly and Company – Ireland

Patient organisations are a key driving force in allowing the pharma industry to become more patient centric; they provide valuable insight into the development and improvement of innovative treatments and practices.

Relationships between pharma companies and patient organisations are regulated through the EFPIA Code and national industry codes to enforce public disclosure of any collaboration. It is integral to follow these guidelines to meet and maintain high standards of transparency and integrity between the pharma industry and patient organisations across Europe.

This Methodological Note is intended to serve as supporting documentation for the Lilly patient organisation report published annually. It underlines the rationale for interactions between Lilly and patient organisations and describes the methods applied to meet the reporting requirements outlined in the EFPIA Disclosure Code and local transparency guidelines where applicable.

Patient Organisations are described as a non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in Europe.

The patient organisation report for each country will outline:

- The type of support Lilly are providing to the patient organisation i.e. – financial, significant indirect, or significant non-financial support
 - o Lilly has set the threshold for significant support at 250 Euro
- The nature of funding or project description for every transaction
- The transaction amount in local currency if there is a monetary value attached

Cross Border Transfer of Values

Lilly define cross-border ToV as a Transfer of Value to a patient organisation where the Lilly division providing the funding is based outside of the country of the benefitting patient organisation. These ToVs are disclosed in the country where the patient organisation has been registered. These cross border ToVs are included in the relevant patient organisation reports as 'International support'.

Charitable Donations

Every year Lilly employees under the guidance of the Corporate Social Responsibility team engage in a variety of fundraising activities and initiatives for charitable organisations, to which Lilly may also contribute.

Donations to Patient Organisations that are solely funded by employee contributions are not reported. In the event where Lilly gift match the employee contribution, the Lilly portion of the donation is reportable.

COVID-19

As per EFPIA guidance, all EFPIA Member Companies must provide detailed explanations on the consequences of COVID-19 on the disclosure data in their methodological note, if applicable. It is important that Lilly adheres to the ethical guidance in light of COVID-19, which has been reflected in the updated EFPIA Code of practice.

Report Regeneration

Eli Lilly and Company Limited, a subsidiary of Eli Lilly and Company, Indianapolis, Indiana, USA
Registered in England No. 00284385 Registered Office, Lilly House
, Basing View, Basingstoke, Hampshire, RG21 4FA

Regarding report corrections, once reports have been published, data corrections may require updates to reports that are publicly available. Once revisions have been made, the publicly available reports may need to be updated to reflect the changes.

Published Date: The publication date equals the date the report is generated via internal systems.

This data will remain published for 3 years in the public domain.